Physician profile
Daniel D Hayes
NPI 1184886301
$6,114.71
in general payments reported to CMS, 2019-2025
29 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $274 · 2021: $190 · 2022: $647 · 2023: $2,955 · 2024: $772 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,642.32 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| New World Medical,INC. | $2,928.81 | 2019-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Clearpath |
| Mallinckrodt Hospital Products INC. | $421.25 | 2021-2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $382.18 | 2019-2021 | |
| Alcon Vision LLC | $355.92 | 2019-2025 | Simbrinza, Tryptyr |
| Abbvie INC. | $349.95 | 2022-2025 | |
| Allergan, INC. | $250.04 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $244.74 | 2019-2023 | |
| Rxsight INC | $131.58 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Oyster Point Pharma, INC. | $125.64 | 2022-2025 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $102.52 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.38 | 2019-2021 | |
| Dompe US, INC. | $97.46 | 2024-2025 | Oxervate |
| Amgen INC. | $84.36 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $81.56 | 2022-2025 | Xiidra |
| Ocular Therapeutix, INC. | $65.58 | 2023-2024 | Dextenza |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $64.77 | 2022-2024 | Cequa |
| Horizon Therapeutics Plc | $56.08 | 2023 | Tepezza |
| Genentech USA, INC. | $45.84 | 2024-2025 | Vabysmo |
| Sight Sciences, INC. | $30.15 | 2022 | |
| Ani Pharmaceuticals, INC. | $29.91 | 2025 | Purified Cortrophin Gel |
| Coherus Oncology, INC. | $29.59 | 2023 | |
| Springworks Therapeutics, INC. | $26.26 | 2025 | Gomekli |
| Halozyme INC | $23.00 | 2024 | Hylenex Recombinant |
| Eyepoint US, INC. | $20.07 | 2020 | |
| Alimera Sciences, INC. | $18.57 | 2020 | |
| Eyevance Pharmaceuticals LLC | $13.94 | 2021 | |
| Rayner Intraocular Lenses Limited | $13.84 | 2025 | Rayone Spheric, Rayone Emv, Rayner Cataract Set 1 |
| Thea Pharma INC. | $13.57 | 2022 | |
| Biotissue Holdings INC. | $9.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hayes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.